Florida Blue — Blue Cross and Blue Shield of Florida, the state's largest health insurer with approximately 6 million members — covers GLP-1 receptor agonists only for type 2 diabetes on commercial plans. Wegovy, Zepbound, and Saxenda prescribed for weight management are a categorical benefit exclusion. Florida Blue does not cover or approve prior authorization requests for off-label indications, including weight loss. The only exception path for obesity-indicated GLP-1s is through Medicare Part D plans, where Wegovy may be covered for cardiovascular risk reduction and MASH.
This guide maps which GLP-1 medications Florida Blue covers, details the prior authorization criteria administered through Prime Therapeutics, explains the weight-loss exclusion, and provides a plan-by-plan coverage summary. It is independent information and not medical advice or reimbursement guidance for a specific patient or plan.
Quick answer
| GLP-1 Drug | Florida Blue Commercial | Florida Blue Medicare (Part D) |
|---|---|---|
| Ozempic (semaglutide injection) | Covered — T2D with PA; preferred | Covered — T2D with PA |
| Mounjaro (tirzepatide injection) | Covered — T2D with PA; preferred | Covered — T2D with PA |
| Rybelsus (semaglutide tablets) | Covered — T2D with PA; preferred | Covered — T2D with PA |
| Trulicity (dulaglutide) | Covered — T2D with PA; preferred | Covered — T2D with PA |
| Wegovy (semaglutide 2.4 mg) | Excluded for weight loss (benefit exclusion) | Covered for CVD risk reduction and MASH with PA; weight loss excluded per CMS |
| Zepbound (tirzepatide) | Excluded (benefit exclusion) | Covered for OSA with PA; weight loss excluded per CMS |
| Saxenda (liraglutide 3 mg) | Excluded (benefit exclusion) | Excluded |
| Victoza (liraglutide) | Not covered on commercial | Covered — T2D with PA |
Key policy dates:
- April 1, 2024: Florida Blue updated GLP-1 prior authorization criteria — providers must now submit clinical documentation of T2D diagnosis and metformin failure
- January 2025: Florida Blue issued provider bulletin confirming GLP-1 coverage for FDA-approved T2D indications only; weight-loss PA submissions result in automatic denial
- 2026 (ongoing): Florida Blue commercial plans maintain T2D-only GLP-1 coverage; Medicare Part D plans expand Wegovy coverage for cardiovascular and MASH indications per CMS
Who this is for
- Florida Blue commercial members (BlueChoice, BlueOptions, BlueSelect, BlueCare, myBlue, SimplyBlue, Truli for Health) and their prescribers
- Florida Blue Medicare members with Part D prescription drug coverage
- Benefit verification specialists and hub teams handling Florida Blue pharmacy claims
- Market access teams at GLP-1 manufacturers tracking Florida Blue policy
- Providers submitting GLP-1 PA requests through CoverMyMeds or Prime Therapeutics
Florida Blue plan structure
Florida Blue operates under GuideWell, a mutual insurance holding company. The key plan types that affect GLP-1 coverage:
- BlueChoice: Preferred provider organization (PPO) commercial plans
- BlueOptions: Health maintenance organization (HMO) commercial plans
- BlueSelect: Narrow-network commercial plans
- myBlue: Individual and family plans
- SimplyBlue: Simplified plan design
- Truli for Health: Small business plans
- Florida Blue Medicare: Medicare Advantage and Part D plans
Each plan type uses a different formulary (Open Medication Guide, NetResults, or ValueScript Rx), but all share the same T2D-only GLP-1 coverage policy for commercial plans.
Type 2 diabetes GLP-1 coverage
Preferred GLP-1 drugs
Florida Blue identifies the following as preferred GLP-1 medications covered for type 2 diabetes:
- Mounjaro (tirzepatide)
- Ozempic (semaglutide injection)
- Rybelsus (semaglutide tablets)
- Trulicity (dulaglutide)
- Victoza (liraglutide) — covered on Medicare plans only; not available on commercial formularies
These medications are placed on preferred tiers of the formulary but require prior authorization.
PA criteria for T2D
Florida Blue administers GLP-1 PA through Prime Therapeutics, its pharmacy benefit manager. The PA criteria for T2D GLP-1 coverage require:
- Documented type 2 diabetes diagnosis: Clinical documentation confirming T2D, including:
- HbA1c results
- Fasting plasma glucose levels
- Provider attestation of diabetes diagnosis
- Metformin trial requirement: Documentation that the patient has tried and failed metformin, other metformin combination drugs, or insulin — this demonstrates medical necessity for GLP-1 approval
- FDA-approved indication: The GLP-1 must be prescribed for an FDA-approved T2D indication only
- No off-label use: Florida Blue does not cover or approve PA requests for off-label indications
From Florida Blue's GLP-1 Drug Class Overview Bulletin:
"Providers are required to provide clinical documentation of type 2 diabetes diagnosis when submitting a request for approval. Providers must submit documentation indicating the patient has tried and failed metformin, other metformin combination drugs, or insulin to demonstrate medical necessity for GLP-1 approval."
Formulary tier placement
Florida Blue's formularies (Open, NetResults, ValueScript Rx) tier GLP-1 T2D medications as follows:
| Drug | Tier | PA | Quantity Limits |
|---|---|---|---|
| Ozempic | Tier 2–3 | Yes | Per FDA max |
| Mounjaro | Tier 2–3 | Yes | Per FDA max |
| Rybelsus | Tier 2 | Yes | 1 tablet/day |
| Trulicity | Tier 2–3 | Yes | Per FDA max |
Tier placement varies by specific formulary and plan type. Higher tiers result in higher member cost-sharing.
Weight-loss GLP-1 exclusion
The exclusion policy
Florida Blue's policy on GLP-1 medications for weight loss is one of the most restrictive among major commercial payers:
- Medications used for weight loss/management are excluded from coverage under Florida Blue's commercial health insurance plans
- Requesting an authorization for Wegovy, Zepbound, Saxenda, or other medications for weight loss/management will result in denial
- This is a benefit exclusion, not a formulary management decision — it cannot be appealed as a medical necessity determination
- Patients will have to pay for these medications out of pocket
From Florida Blue's January 2025 provider bulletin:
"If you believe a GLP-1 medication is appropriate for a patient to address weight loss/management, please do not submit a request to Prime Therapeutics to review. Be sure to let the patient know the GLP-1 drugs will not be covered, and it will have to be paid for out of pocket."
Practical implications
- No PA submission for weight loss: Florida Blue explicitly asks providers not to submit PA requests for GLP-1 weight-loss medications, as they will be automatically denied
- No off-label coverage: Even if a provider believes a GLP-1 is medically necessary for weight management, the benefit exclusion applies regardless of BMI, comorbidities, or clinical justification
- No formulary exception: The exclusion is embedded in the plan benefit design, not in the formulary, so formulary exception requests are not applicable
- Employer plan variation: Self-funded employer plans may have different coverage rules; verify with the plan administrator
Why Florida Blue excludes weight-loss GLP-1s
Florida Blue has communicated that the exclusion is driven by cost considerations. GLP-1 weight-loss medications are expensive (Wegovy retail approximately $1,350/month), require long-term use to maintain effectiveness, and covering them would increase premiums for all members. This aligns with broader industry trends — KFF research found that ACA marketplace plans rarely cover GLP-1 drugs for obesity.
Medicare Part D GLP-1 coverage
Florida Blue Medicare Advantage and stand-alone Part D plans follow CMS rules for GLP-1 coverage:
T2D coverage
- GLP-1 medications for T2D are covered with PA on Florida Blue Medicare Part D plans
- Same preferred drug list (Ozempic, Mounjaro, Rybelsus, Trulicity) with PA requirements
- Victoza is covered under Medicare plans (not commercial)
Wegovy for cardiovascular risk reduction
- CMS has clarified that Wegovy is coverable under Medicare Part D for cardiovascular risk reduction in adults with established cardiovascular disease and obesity/overweight
- This is a separate indication from weight loss and follows FDA labeling
- Florida Blue Medicare covers Wegovy for this indication with PA
- Requires documented cardiovascular disease and BMI ≥ 27 kg/m²
Wegovy for MASH
- The FDA approved Wegovy for noncirrhotic MASH with F2–F3 fibrosis
- Florida Blue Medicare Part D covers Wegovy for MASH with PA
- Requires hepatologist/gastroenterologist consultation and fibrosis confirmation
Zepbound for OSA
- The FDA approved Zepbound for obstructive sleep apnea in adults with obesity
- Florida Blue Medicare may cover Zepbound for OSA with PA
- Weight-loss coverage for Zepbound remains excluded per CMS rules
Prime Therapeutics PA process
Florida Blue contracts with Prime Therapeutics for pharmacy benefit management, including GLP-1 prior authorization:
PA submission
- PA requests are submitted through CoverMyMeds or via Prime Therapeutics directly at myPrime.com
- Providers can find GLP-1 PA criteria questions on myPrime.com before submitting
- For Medicare plans, PA is submitted through the same process
Key considerations for PA submission
- Only submit for T2D indications: Do not submit PA requests for weight-loss GLP-1 medications — they will be denied and waste administrative time
- Include complete diabetes documentation: A1C results, FPG levels, and provider attestation
- Document metformin trial: Include records of metformin use, duration, and reason for switching (inefficacy or intolerance)
- Check formulary first: Verify the specific GLP-1 medication's tier and PA requirements on the patient's formulary before prescribing
Common denial reasons and strategies
Top denial reasons
- Weight-loss indication: Any GLP-1 request for weight management is automatically denied — this is the most common and least appealable denial
- Missing T2D documentation: Failure to provide A1C, FPG, or provider attestation of diabetes diagnosis
- No metformin trial: Patient has not tried and failed metformin, metformin combinations, or insulin
- Off-label request: GLP-1 prescribed for an indication not approved by FDA or not covered under the plan
- Missing clinical records: Incomplete documentation submitted with the PA request
Strategies for prescribers
- For T2D patients: Ensure complete documentation before PA submission — A1C, metformin trial, provider attestation
- For weight-loss patients: Inform patients that Florida Blue commercial plans do not cover GLP-1s for weight loss; discuss:
- Manufacturer savings programs (Novo Nordisk Wegovy savings card, Eli Lilly Zepbound savings card)
- HSA/FSA eligible expenses for out-of-pocket costs
- Florida Blue wellness programs at Florida Blue Centers (nutrition, weight management, exercise — covered at no extra cost)
- For Medicare patients with CVD or MASH: Submit Wegovy PA with documented cardiovascular disease or MASH diagnosis; this has a viable coverage path
- For employer self-funded plans: Contact the plan administrator directly — self-funded plans may have different GLP-1 coverage rules than Florida Blue's standard formulary
Prescribing checklist
Before submitting a GLP-1 prior authorization to Florida Blue:
- Confirm the patient's plan type (commercial vs. Medicare) and formulary
- Determine the clinical indication (T2D, CVD risk reduction, MASH, OSA, or weight loss)
- If T2D: document diagnosis with A1C and/or FPG results
- If T2D: document metformin trial (duration, dose, outcome)
- Do NOT submit PA for weight-loss GLP-1 on commercial plans — it will be denied
- If Medicare: check Part D formulary for Wegovy CVD/MASH or Zepbound OSA coverage
- Submit through CoverMyMeds or Prime Therapeutics at myPrime.com
- Inform patient of expected coverage and out-of-pocket costs
What to monitor
- Florida Blue formulary updates: Quarterly formulary reviews may change tier placement for GLP-1 T2D medications
- State legislation: Florida has not enacted a GLP-1 coverage mandate, but legislative proposals could emerge
- CMS Medicare GLP-1 Bridge: Expected to expand Medicare coverage for GLP-1 weight-loss drugs starting mid-2026; could shift Florida Blue Medicare policy
- New Wegovy formulations: Oral Wegovy tablets and higher-dose injectable (7.2 mg) may affect formulary placement
- Employer plan changes: Annual enrollment periods may bring changes to employer-sponsored GLP-1 coverage
Sources
- Florida Blue, GLP-1 Prior Authorization Requirement for Commercial Plans, January 2025: https://files.guidewell.com/m/7bf6733fcce9a9ab/original/providers-news-2025-pharmacy-glp-commercial-prior-auth-requirement-01-2025.pdf
- Florida Blue, GLP-1 Drug Class Overview Bulletin: https://files.guidewell.com/m/3179dbafc2d11f32/original/providers-news-2024-pharmacy-glp-drug-class-04-01-24.pdf
- Florida Blue, April 2026 Open Medication Guide: http://www.bcbsfl.com/DocumentLibrary/Providers/Content/MedGuide.pdf
- Florida Blue, April 2026 NetResults Medication Guide: https://www.bcbsfl.com/DocumentLibrary/Providers/Content/NetResults_A_MedGuide.pdf
- Florida Blue, Provider Prior Authorization: https://www.floridablue.com/providers/medical-pharmacy-info/prior-authorization
- Prime Therapeutics, GLP-1 Pipeline Update, February 2026: https://www.primetherapeutics.com/glp-1-pipeline-update-february-2026
- CMS, Medicare Part D Drug Coverage: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn
- FDA, Wegovy (semaglutide) prescribing information and FDA-approved indications: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011s012s013s014lbl.pdf
- KFF, Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans, June 2024: https://www.kff.org/affordable-care-act/costly-glp-1-drugs-are-rarely-covered-for-weight-loss-by-marketplace-plans
